Cerevel Therapeutics Holdings Inc (CERE) Return on Equity ROE from the first quarter 2024 to first quarter 2023 and annually, average high and low, overall ranking from Mar 31 2024 to Mar 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cerevel Therapeutics Holdings Inc   (NASDAQ: CERE)

Cerevel Therapeutics Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cerevel Therapeutics Holdings Inc in the first quarter 2024?
Cerevel Therapeutics Holdings Inc recorded a cumulative net loss of $-460 million during 12 months ending in the first quarter 2024, resulting in a negative return on equity (ROE) of -98.94%.

Within the Major Pharmaceutical Preparations industry 263 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2023 from 0 to 3557.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter
Y / Y Equity Change 30.75 % 29.26 % -54.76 % -22.6 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -460 -433 -393 -397 -388
Return On Equity (TTM) -98.94 % -100.14 % -99.72 % -83.19 % -77.15 %
CERE's Total Ranking # 3557 # 0 # 3510 # 2694 # 3083
Equity (TTM) in Millions 564 674 273 351 432
Seq. Equity Change -16.22 % 146.83 % -22.12 % -18.81 % -17.18 %
Seq. Net Income Change - - - - -

Back to CERE Management Effectiveness >> CERE's 5 Years Annual ROE >> Compare CERE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 264
Sector # 605
Overall # 3557

Return On Equity Statistics
High Average Low
-52.49 %
-148.4 %
-617.23 %
(March 31, 2013)   (May 31 2016)





CERE Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Aug 31 2015)
2015
Total Equity in Millions 674 521 579 385 4
Y / Y Equity Change 29.26 % -9.93 % 50.51 % 9026.99 % -84.74 %
Net Income in Millions -433 -352 -225 -144 -28
Y / Y Net Income Change - - - - -
Return On Equity -64.24 % -67.44 % -38.94 % -37.55 % -668.31 %

Back to CERE Management Effectiveness >> CERE's 5 Years Annual ROE >> Compare CERE ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CERE's' Return on Equity at Yahoo Finance
CERE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CERE's Competitors
Subscribers only: Roe for Cerevel Therapeutics Holdings Inc 's Suppliers
Subscribers only: Return On Equity for CERE's Customers




Companies with similar Return On Equity at Mar 31 2024, within Healthcare Sector ROE

Date modified: 2026-09-12T06:24:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.